1	Tit	le: Underdiagnosis of myalgic encephalomyelitis/chronic fatigue syndrome-like illness in a large
2	int	egrated healthcare system — Kaiser Permanente Northern California, 2022-2023
3		
4	She	ort Title: Underdiagnosis of ME/CFS-like illness
5		
6	Au	<b>thors:</b> Mariah S. Wood <sup>1*</sup> , Nicole Halmer <sup>1</sup> , Jeanne Bertolli <sup>2</sup> , Laura B. Amsden <sup>1</sup> , Joshua R. Nugent <sup>1</sup> , Jin-
7	Ma	nn S. Lin <sup>2</sup> , Gretchen Rothrock <sup>3</sup> , Joelle Nadle <sup>3</sup> , Shua J. Chai <sup>2,3</sup> , Jamila H. Champsi <sup>4,5</sup> , James Yang <sup>4,6</sup> ,
8	Eliz	abeth R. Unger <sup>2</sup> , Jacek Skarbinski <sup>1,4,7,8</sup> for STOP-ME/CFS and COVID-SELECT
9		
10	Au	thor Affiliations:
11	1.	Division of Research, Kaiser Permanente Northern California, Pleasanton, California, United States of
12		America
13	2.	Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic
14		Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of
15		America
16	3.	California Emerging Infections Program, Oakland, California, United States of America
17	4.	The Permanente Medical Group, Kaiser Permanente Northern California, Oakland, California, United
18		States of America
19	5.	Department of Infectious Diseases, South San Francisco Medical Center, Kaiser Permanente
20		Northern California, South San Francisco, California, United States of America
21	6.	Department of Adult and Family Medicine, Roseville Medical Center, Kaiser Permanente Northern
22		California, Roseville, California, United States of America
23	7.	Department of Infectious Diseases, Oakland Medical Center, Kaiser Permanente Northern California,
24		Oakland, California, United States of America

- 25 8. Physician Researcher Program, Kaiser Permanente Northern California, Oakland, California, United
- 26 States of America
- 27
- 28 \*Corresponding author
- 29 E-mail: mariah.s.wood@kp.org
- 30
- 31 Keywords: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
- 32
- 33 **Disclaimer:** The opinions expressed by authors contributing to this journal do not necessarily reflect the
- 34 opinions of the Centers for Disease Control and Prevention or the institutions with which the authors
- 35 are affiliated

# 36 Abstract

- 37 Background: Surveillance of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a chronic,
- 38 debilitating multisystem illness, is challenging because ME/CFS can be under-recognized in healthcare
- 39 settings.
- 40 Methods: Using a population-based panel study of 9,820 adult members of Kaiser Permanente Northern
- 41 California (KPNC), a large, integrated healthcare system, we compared survey-defined ME/CFS-like
- 42 illness with presence of an ME/CFS diagnosis in the electronic health record (EHR) to evaluate ME/CFS
- 43 underdiagnosis.
- 44 Results: Of those with survey-defined ME/CFS-like illness, an estimated 97.8% (95% confidence interval
- 45 [CI] 97.1%-98.4%) did not have an ME/CFS diagnosis in the EHR. The group without EHR diagnosis was

46 younger, less likely to identify as white non-Hispanic, and more likely to have developed fatigue in the

- 47 past three years than the EHR diagnosed group. Both diagnosed and undiagnosed ME/CFS-like illness
- 48 groups had significantly impaired physical, cognitive, and social functioning, and significantly worse
- 49 mental health and anxiety than those without ME/CFS-like illness.
- 50 Conclusion: ME/CFS is underdiagnosed in the Kaiser Permanente Northern California healthcare system.
- 51 Enhanced syndromic surveillance that characterizes patients with ME/CFS who have not been diagnosed
- 52 has the potential to increase timely recognition of ME/CFS.

### 53 Introduction

54 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic, debilitating 55 multisystem illness that affects millions of people worldwide (1). The Institute of Medicine (IOM) 2015 56 diagnostic criteria require a substantial reduction in the ability to engage in pre-illness activity for more 57 than six months, accompanied by fatigue of new or definite onset not resulting from excessive exertion 58 and that is unrelieved by rest, post-exertional malaise, unrefreshing sleep, and either cognitive 59 impairment or orthostatic intolerance (2,3). Given the lack of a diagnostic biomarker, ME/CFS is 60 diagnosed by clinicians based on patient self-report of symptoms that meet the IOM diagnostic criteria 61 after full clinical evaluation to identify other conditions that could contribute to symptoms (4). Prior 62 studies have suggested that most ME/CFS patients are undiagnosed (1), and the number of people with 63 undiagnosed ME/CFS may have recently increased given ME/CFS is a possible outcome of SARS-CoV-2 64 infection (5). Understanding the extent of ME/CFS underdiagnosis is crucial for mobilizing action to 65 improve identification and subsequent care for those with ME/CFS. We estimate the prevalence of 66 undiagnosed ME/CFS-like illness in a large, integrated healthcare system over a two-year study period, 67 compare demographics, healthcare utilization, and health-related quality of life among undiagnosed and 68 diagnosed persons, and suggest measures that could improve rates of diagnosis. 69 70 Methods 71 In collaboration with Kaiser Permanente Northern California (KPNC), the California Emerging

Infections Program conducts enhanced syndromic surveillance for ME/CFS through the Surveillance to
Optimize Protocols for Early Identification and Subgrouping of ME/CFS (STOP ME/CFS) project. STOP
ME/CFS involves annual surveys to identify and follow patients with ME/CFS-like illness among KPNC's
4.5 million members, who are demographically similar to the California population (6). The study was
approved by the KPNC Institutional Review Board (IRB # 1692449). Informed written consent was

obtained for all participants in this study. This activity was reviewed by the CDC and was conducted
 consistent with applicable federal law and CDC policy.

79 A stratified random sample of adult English-speaking KPNC members who had been members 80 for at least one year and who had a valid email address on file were recruited from seven mutually-81 exclusive strata, including: 1) ME/CFS diagnosis in the electronic health record (EHR); 2) post-COVID 82 conditions diagnosis in the EHR; 3) persons at higher risk for ME/CFS based on an internally-created 83 predictive model; 4) persons who had COVID-19 before July 5, 2021; 5) persons who had COVID-19 84 between July 5, 2021 and December 14, 2021; 6) persons who had COVID-19 after December 15, 2021 85 through beginning of recruitment (May 9, 2022); and 7) persons who did not fit into any above strata. 86 (For full sampling strategy see methods section and flow diagram in the prior paper stemming from the

87 STOP ME/CFS project (7)).

88 To select for people who were more likely to have the relatively rare outcome of ME/CFS, 89 persons were oversampled from strata one to three. In stratum one, 8,061 (98.5%) of 8,182 persons 90 were sampled. In stratum two, 6,057 (98.9%) of 6,126 were sampled. In stratum three, 29,720 (99.1%) 91 of 30,000 were sampled. Within each of strata four through seven, a simple random sample was 92 applied. In stratum four, 11,046 (8.3%) of 133,114 were sampled. In stratum five, 10,389 (18.2%) of 93 57,127 were sampled. In stratum six, 10,982 (8.6%) of 128,206 were sampled and in stratum seven, 94 22,250 (0.9%) of 2,382,619 persons were sampled. Sampled persons were invited to participate in an 95 online survey from July 10 to October 17, 2022. Of 98,505 eligible sampled members, 9,825 (10.0%) 96 completed the survey in year one. In year two, all respondents from year one were contacted again 97 from May 1 to November 27, 2023; of those respondents, 6,393 (65.1%) completed the survey again in 98 year two (since recruitment, five respondents requested data removal; the updated number of 99 respondents is 9,820). Participants were offered a \$10 gift card each time they completed a survey.

100 The survey assessed sociodemographic characteristics, IOM ME/CFS diagnostic criteria based on 101 standardized scores on symptom questionnaires, COVID-19 history, and health-related quality of life 102 using established instruments (see footnote in Table 2)). Linked EHR data were used to assess ME/CFS 103 and related diagnoses, COVID-19 history, body mass index (BMI), Charlson comorbidity index score, and 104 outpatient primary care utilization (in-person, video, and telephone visits with a provider in family 105 medicine, internal medicine, or obstetrics/gynecology). Of the respondents, 645 in year one and 316 in 106 year two (not mutually exclusive) met criteria for survey-identified ME/CFS-like illness based on IOM 107 ME/CFS diagnostic criteria (Supplemental Table 1). In total, 798 persons had ME/CFS-like illness in either 108 year one, year two, or both. Persons with survey-identified ME/CFS-like illness were classified as either 109 having undiagnosed ME/CFS if they had no recorded ME/CFS diagnosis in their EHR at any time 110 (identified by either International Classification of Disease [ICD]-9 codes 780.71 or 323.9, or ICD-10 111 codes G93.32, R53.82, or umbrella codes G93.3) or having diagnosed ME/CFS if a ME/CFS diagnosis was 112 documented in their EHR. The primary outcome of interest was prevalence of an EHR ME/CFS diagnosis 113 among those who qualified for survey-identified ME/CFS-like illness. Secondary outcomes of interest 114 included characteristics and functional status of respondents stratified by presence of an EHR ME/CFS 115 diagnosis. 116 Sampling weights were calculated equal to the inverse of the probability of sample selection. 117 Non-response weights were estimated using Super Learner, an ensemble machine learning method that 118 uses a weighted combination of candidate algorithms to optimize predictive performance via cross-119 validation (8). We modeled the probability of survey response within each stratum, adjusting for current 120 age, race and ethnicity, sex, Charlson comorbidity index (CCI) score within the last year (9,10), and body

121 mass index (BMI) within the last two years and generated non-response weights as the inverse of the

122 predicted probability of response. Sampling strata four to seven had higher maximum non-response

123 weights and were trimmed at the 99<sup>th</sup> percentile. Sampling and non-response weights were multiplied

124	together to determine final survey weights. The weighted sample was compared to the original eligible
125	population using standardized mean differences to ensure the demographic distribution between
126	sample and eligible population was not substantially different (Supplemental Table 3 in the prior paper
127	stemming from the STOP ME/CFS project (7)). For those who had repeated observations (responded
128	both years), final survey weights were divided by two, and half of each weight was applied to each year.
129	All estimates are for the two-year period and include sampling weights and non-response weights as
130	well as adjustment for repeated observations on participants who responded in both years one and two.
131	SF-36 scores and PROMIS cognitive function scores were converted into T-scores (11–13). Associations
132	between the groups were tested using the Wilcoxon rank-sum test for complex survey samples and chi-
133	square test with Rao & Scott's second-order correction; p-values were adjusted for multiple
134	comparisons (14). Non-response weights were generated using the SuperLearner package (15),
135	weighted, repeated-measures survey data were generated using the survey package (16), and tables of
136	weighted data and p-values were generated using the gtsummary package (17).
137	
138	Results
139	Using a weighted survey of 9,820 adult Kaiser Permanente members over two years, we
140	estimated that 1.8% (95% confidence interval [CI] 1.3%-2.2%) of adult members had survey-identified
141	ME/CFS-like illness during the two-year study period. Among those with survey-identified ME/CFS-like
142	illness, an estimated 97.8% (CI 97.1%-98.4%) did not have any ME/CFS diagnosis in their EHR, with only
143	2.2% (CI 1.6%-2.9%) having a ME/CFS diagnosis in their health record. Those without an EHR ME/CFS
144	diagnosis were younger (mean age 44 vs. 51) and less likely to identify as White, non-Hispanic (46% vs.
145	66%) compared to those with an EHR ME/CFS diagnosis (Table 1). Among all those with survey-identified

146 ME/CFS-like illness, the average number of primary care visits over the past three years was 11 (median

147 9, range 1 to 135); 100% of those without an EHR diagnosis and 98% of those with an EHR diagnosis had

148 at least one virtual or in-person primary care visit in the last three years. Among all those with ME/CFS-149 like illness, persons without an EHR ME/CFS diagnosis were significantly more likely to report fatigue 150 onset less than three years prior to survey date (53% vs. 28%) than persons with an EHR ME/CFS 151 diagnosis. Moreover, despite reporting these symptoms on the survey, persons with ME/CFS-like illness 152 and without an EHR ME/CFS diagnosis were significantly less likely to have any diagnosis in their EHR of 153 fatigue (47% vs. 92%), sleep issues (39% vs. 69%), or cognitive impairment (9% vs. 27%) compared to 154 persons with ME/CFS-like illness and an EHR ME/CFS diagnosis. 155 Both groups with survey-identified ME/CFS-like illness, either diagnosed or undiagnosed, 156 reported significantly lower quality of life than a group of KPNC members without ME/CFS-like illness 157 (Table 2). The mean SF-36 T-score was 32 for those with ME/CFS-like illness without an EHR diagnosis, 158 30 for those with ME/CFS-like illness and an EHR ME/CFS diagnosis, and 48 for those without ME/CFS-159 like illness; an SF-36 score of 50, with a standard deviation of 10, is the United States population norm 160 (13). Scores on instruments assessing depression, anxiety, cognitive function, and orthostatic symptoms 161 also indicated significant differences for both groups with ME/CFS-like illness compared to the general 162 population. Generally, persons with ME/CFS-like illness and an EHR diagnosis had lower well-being 163 scores than those with ME/CFS-like illness without an EHR diagnosis; however, persons without an EHR 164 ME/CFS diagnosis had a significantly lower SF-36 mental health T-score (30 vs. 34) and significantly 165 higher anxiety score on GAD-2 (worse anxiety) (4 vs. 3) than persons with an EHR ME/CFS diagnosis. 166 167 Discussion

In an integrated healthcare system with 2.7 million adult members, an estimated 1.8% had
symptoms consistent with ME/CFS-like illness during a two-year period. Of those with ME/CFS-like
illness, 97.8% had no documentation of an ME/CFS diagnosis, despite a high level of primary care
utilization; 53% of those with ME/CFS-like illness and no EHR diagnosis reported fatigue began less than

172 three years prior. Surveying medical records alone would not have uncovered this younger, more racially 173 diverse group with recent-onset ME/CFS-like illness. These findings suggest that many people with 174 ME/CFS are not recognized, particularly those with recent onset. Earlier diagnosis of ME/CFS by 175 clinicians might facilitate improvement in outcomes and prevention of disease progression for this group 176 (18). Persons with ME/CFS-like illness without an EHR diagnosis had worse anxiety than persons with 177 ME/CFS-like illness and an EHR diagnosis, suggesting a possible effect of unrecognized illness on mental 178 health among people with ME/CFS symptoms. 179 This report documents potential underdiagnosis of ME/CFS by healthcare providers, even in an 180 integrated healthcare system with accessible primary care services. Numerous factors may contribute to 181 the high level of underdiagnosis of ME/CFS, including the lack of a diagnostic biomarker, a low level of 182 dissemination of standardized screening and assessment tools, limited uptake of clinician training on 183 ME/CFS, a low-level of patient awareness of ME/CFS, misconceptions among clinicians that the illness is 184 psychogenic in nature or does not exist, and the fact that ME/CFS symptoms can overlap with other 185 illnesses (1,19). The symptoms of the undiagnosed group may provide insight into screening for and 186 monitoring ME/CFS earlier in the illness course. 187 These findings indicate the importance of enhanced symptom-based surveillance as an initial 188 step in recognizing undiagnosed ME/CFS, as those with undiagnosed ME/CFS-like illness would not have 189 been identified without this project's symptom-based surveillance efforts. Enhanced syndromic

surveillance has the potential to increase timely recognition of ME/CFS. Public communication

191 campaigns could also promote earlier recognition of ME/CFS symptoms, which could lead to earlier

192 care-seeking and care provision. One avenue for public communication is via interactive web-based

- 193 training for primary healthcare providers and patients. Web-based training could provide resources for
- 194 managing this complex illness but has had limited implementation to date. Public health detailing, which

involves educational visits by public health officials to providers, might also provide support to clinicians,as it has for other chronic conditions (20).

197	The findings in this report are subject to limitations. First, we assessed ME/CFS-like illness using
198	established IOM ME/CFS criteria based on self-reported symptom frequency, severity, and duration, but
199	did not conduct in-person clinical examinations and interviews to establish a definitive clinical ME/CFS
200	diagnosis; some persons classified as having survey-identified ME/CFS in this study might have an
201	alternative diagnosis or condition that explains their symptoms, which might have inflated our estimate
202	of persons with ME/CFS-like illness. Similarly, we used ICD-9/10 codes to identify persons who had an
203	ME/CFS diagnosis documented in their EHR; ICD-9/10 coding has limitations as a surveillance tool due to
204	the potential for misclassification. Second, our overall survey response rate was 10%; though results
205	were weighted to be representative of the eligible KPNC adult population (see Supplemental Table 3 in
206	prior paper (7)), lower response rates limit the generalizability of results. Third, we only included
207	persons with English listed as their preferred language; 9% of KPNC members prefer a language other
208	than English and were not included in this study.
209	The results suggest that underdiagnosis of ME/CFS is common despite high levels of care
210	utilization in the Kaiser Permanente Northern California integrated healthcare system. Several strategies
211	could be implemented to attempt to address underdiagnosis, including continued syndromic
212	surveillance, web-based training for providers and patients, and public health detailing. Improved
213	ascertainment of ME/CFS by the medical system is critical for patient care and well-being and has the
214	potential to decrease patient morbidity from ME/CFS through earlier recognition and intervention.

### 215 Acknowledgements

- 216
- All authors contributed to conceptual ideas and contributed to methodology. MSW, JSL, ERU, JS
- 218 contributed to operationalization of case-definition and survey instrument scoring; MSW, JRN, JS
- 219 contributed to formal analysis; MSW, JS contributed to writing and original draft preparation; all authors
- 220 contributed to writing, reviewing, and editing the manuscript; JS, JB, GR supervised the work. The
- funders contributed to the study design, decision to publish, and preparation of the manuscript. They
- did not contribute to the data collection or formal analysis.
- 223 The authors are grateful to all Kaiser Permanente members without whom this study would not
- have been possible.

## 225 References

- Bateman L, Bested AC, Bonilla HF, Chheda BV, Chu L, Curtin JM, et al. Myalgic
   Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management. Mayo Clinic
   Proceedings. 2021 Nov;96(11):2861–78.
- IOM 2015 Diagnostic Criteria | Diagnosis | Healthcare Providers | Myalgic
   Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) | CDC [Internet]. 2021 [cited 2023 Apr 17].
   Available from: https://www.cdc.gov/me-cfs/healthcare-providers/diagnosis/iom-2015-diagnosticcriteria.html
- Institute of Medicine (U.S.), editor. Beyond myalgic encephalomyelitis/chronic fatigue syndrome:
   redefining an illness. Washington, D.C: The National Academies Press; 2015. 1 p.
- Grach SL, Seltzer J, Chon TY, Ganesh R. Diagnosis and Management of Myalgic
   Encephalomyelitis/Chronic Fatigue Syndrome. Mayo Clinic Proceedings. 2023 Oct;98(10):1544–51.
- 237 5. Robertson MM, Qasmieh SA, Kulkarni SG, Teasdale CA, Jones HE, McNairy M, et al. The
  238 Epidemiology of Long COVID in US Adults. Clinical Infectious Diseases. 2022 Dec 21;ciac961.
- Davis AC, Voelkel JL, Remmers CL, Adams JL, McGlynn EA. Comparing Kaiser Permanente Members
   to the General Population: Implications for Generalizability of Research. TPJ. 2023 Jun 15;27(2):87–
   98.
- Wood MS, Halmer N, Bertolli J, Amsden LB, Nugent JR, Lin JMS, et al. Impact of COVID-19 on myalgic
   encephalomyelitis/chronic fatigue syndrome-like illness prevalence: A cross-sectional survey. Yon
   DK, editor. PLoS ONE. 2024 Sep 18;19(9):e0309810.
- 245 8. van der Laan MJ, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol. 2007;6:Article25.
- 246 9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity
  247 in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
- 248 10. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM
   249 administrative databases. J Clin Epidemiol. 1992 Jun;45(6):613–9.
- 250 11. Ware JE. SF-36 Health Survey Update: Spine. 2000 Dec;25(24):3130–9.
- Patient-Reported Outcomes Measurement Information System Cognitive Function [Internet].
   HealthMeasures; 2019 [cited 2023 Aug 18]. Available from:
   https://staging.healthmeasures.net/images/PROMIS/manuals/PROMIS\_Cognitive\_Function\_Scoring
   Manual.pdf
- 255 13. Ware J, Kosinski M, Bjorner J, Turner-Bowker D, Gandek B, Maruish M. User's manual for the SF 256 36v2 Health Survey. QualityMetric Incorporated; 2007.
- 257 14. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to
   258 Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological). 1995
   259 Jan;57(1):289–300.

- 260 15. Polley E, LeDell E, Kennedy C, van der Laan M. \_SuperLearner: Super Learner Prediction\_. [Internet].
   2023. Available from: https://github.com/ecpolley/SuperLearner
- 262 16. Lumley T. Complex Surveys: A Guide to Analysis Using R. John Wiley and Sons; 2010.
- 263 17. Sjoberg D D, Whiting K, Curry M, Lavery J A, Larmarange J. Reproducible Summary Tables with the
   264 gtsummary Package. The R Journal. 2021;13(1):570.
- 265 18. Bernhoff G, Rasmussen-Barr E, Bunketorp Käll L. A comparison of health-related factors between
  266 patients diagnosed with ME/CFS and patients with a related symptom picture but no ME/CFS
  267 diagnosis: a cross-sectional exploratory study. J Transl Med. 2022 Dec 9;20(1):577.
- 268 19. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness [Internet].
  269 Washington, D.C.: National Academies Press; 2015 [cited 2024 Feb 12]. Available from:
  270 http://www.nap.edu/catalog/19012
- 271 20. O'Brien MA, Rogers S, Jamtvedt G, Oxman A, Odgaard-Jensen J, Kristoffersen DT, et al. Educational
   272 outreach visits: effects on professional practice and health care outcomes. CDSR [Internet]. 2007
   273 Oct 17 [cited 2024 Nov 3]; Available from: http://doi.wiley.com/10.1002/14651858.CD000409.pub2

Table 1. Demographics and characteristics of persons with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-like illness<sup>a</sup> on survey, by presence of ME/CFS diagnosis in the electronic health record (EHR) A. ME/CFS-like B. ME/CFS-like illness. no illness, ME/CFS C. No ME/CFS-like Overall ME/CFS p-values diagnosis in illness diagnosis in EHR EHR A vs. A vs. B nb % (CI)<sup>b</sup> nb % (CI)<sup>b</sup> nb nb % (CI)<sup>b</sup> % (CI)<sup>b</sup> Bc vs. C<sup>d</sup> Unweighted number of 1.7 (1.3, 0.04 (0.03, respondents 473 144 98 (98, 99) 9,820 100 9,202 2.2) 0.05) (weighted row percent (CI)) Age in years (weighted mean 44 (40, 48) 0.003 0.008 50 (49, 51) 51 (49, 53) 50 (49, 51) (CI)) Age in years 0.037 0.02 18-34 1,595 25 (23, 27) 33 (22, 46) 13 (9, 20) 1,505 25 (23, 27) 69 20 35-49 152 2,381 26 (24, 27) 27 (18, 39) 41 30 (23, 38) 2,187 26 (24, 27) 50-64 3,302 24 (22, 26) 201 31 (20, 45) 57 40 (33, 48) 3,043 24 (22, 26) 65+ 2,542 25 (24, 27) 50 8 (4, 17) 26 17 (12, 23) 2,466 26 (24, 27) Self-reported 0.041 0.382 race/ethnicity Asian 16 (8, 29) 4 4 (1, 9) 1,310 22 (20, 24) 30 1,275 22 (20, 24) Black 480 6 (5, 7) 9 (3, 25) 5 (2, 11) 448 26 5 6 (5, 7) Latino/Hispanic 1,594 17 (16, 19) 101 24 (15, 36) 20 19 (12, 27) 1.473 17 (16, 19) White 5,860 50 (48, 52) 262 46 (34, 59) 105 66 (57, 74) 5,492 50 (48, 52) Other/unknown 576 5 (4, 6) 5 (3, 11) 53 10 7 (4, 12) 513 5 (4, 6) Sex 0.774 0.042 115 Female 6,676 58 (56, 60) 367 73 (59, 83) 75 (67, 82) 6.193 58 (56, 60) Male 3.144 42 (40, 44) 105 27 (17, 41) 29 25 (18, 33) 3.009 42 (40, 44) Charlson < 0.001 comorbidity index 0.141 score 0 or no visits 4,930 62 (60, 64) 195 60 (47, 72) 49 32 (25, 39) 4,685 62 (60, 64) 1-2 3,307 25 (24, 27) 189 20 (13, 29) 64 46 (38, 54) 3,053 25 (24, 27) 3+ 1,582 13 (11, 14) 88 20 (11, 34) 22 (16, 30) 1.463 12 (11, 14) 31 Body mass index, 0.774 0.02 kg/m<sup>2</sup> < 30 5,899 63 (61, 65) 210 48 (35, 61) 83 57 (49, 65) 5,605 63 (61, 65) 34 (32, 36) >= 30 3,820 34 (32, 36) 262 51 (38, 63) 61 43 (35, 51) 3,497

Table 1. Demographics and characteristics of persons with myalgic encephalomyelitis/chronic fatigue syndrome         (ME/CFS)-like illness <sup>a</sup> on survey, by presence of ME/CFS diagnosis in the electronic health record (EHR)										
	Overall		A. N ill l dia	ME/CFS-like Iness, no ME/CFS agnosis in EHR	B. ME/CFS-like illness, ME/CFS diagnosis in EHR		C. No ME/CFS-like illness		p-values	
	n <sup>ь</sup>	% (CI) <sup>ь</sup>	nb	% (CI) <sup>ь</sup>	nb	% (CI)⁵	n <sup>b</sup>	% (CI) <sup>ь</sup>	A vs. B <sup>c</sup>	A vs. B vs. C <sup>d</sup>
Number of visits with any primary care provider, last 3 years ( weighted mean (CI))		7 (7, 8)		11 (10, 13)		17 (15, 19)		7 (7, 7)	0.007	<0.001
Outpatient primary care visit in last 3 years, either virtual or in person	9,616	93 (92, 94)	471	100 (100, 100)	142	98 (95, 99)	9,003	93 (92, 94)	<0.001	<0.001
Self-reported diagnosis of ME/CFS									<0.001	<0.001
Yes	555	0 (0, 1)	38	2 (1, 5)	87	59 (51, 67)	430	0 (0, 1)		
No	6,568	61 (59, 63)	370	87 (78, 93)	41	30 (24, 38)	6,156	60 (59, 62)		
Don't know/no response	2,696	39 (37, 41)	64	11 (5, 21)	15	11 (7, 16)	2,616	39 (37, 41)		
Fatigue onset									0.001	<0.001
Less than 3 years	3,341	29 (27, 30)	235	53 (41, 65)	39	28 (22, 36)	3,067	28 (27, 30)		
Greater than or equal to 3 years	6,478	71 (70, 73)	238	47 (35, 59)	105	72 (64, 78)	6,135	72 (70, 73)		
Clinician diagnosis in EHR <sup>e</sup>										
Clinician diagnosis of fatigue	6,052	27 (25, 28)	415	47 (34, 59)	133	92 (87, 95)	5,504	26 (25, 28)	<0.001	<0.001
Clinician diagnosis of sleep issues	4,080	20 (19, 22)	300	39 (28, 52)	100	69 (60 <i>,</i> 76)	3,679	20 (18, 21)	<0.001	<0.001
Clinician diagnosis of cognitive impairment	1,027	4 (3, 4)	89	9 (5, 16)	40	27 (21, 35)	898	3 (3, 4)	0.001	0.001
Clinician diagnosis of orthostatic intolerance	414	2 (1, 2)	38	9 (3, 23)	25	18 (12, 25)	351	2 (1, 2)	0.193	<0.001
Work status									0.002	<0.001
Employed	5,733	65 (63, 67)	225	59 (46, 71)	45	32 (25, 40)	5,463	65 (64, 67)		
Unable to work due to health disability	990	2 (2, 3)	161	22 (13, 34)	72	50 (43, 58)	756	2 (2, 3)		

 Table 1. Demographics and characteristics of persons with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-like illness<sup>a</sup> on survey, by presence of ME/CFS diagnosis in the electronic health record (EHR)

	O	verall	A. N ill f dia	1E/CFS-like ness, no ME/CFS agnosis in EHR	B. N illne dia	1E/CFS-like ss, ME/CFS agnosis in EHR	C. No ME/CFS-like illness		p-values	
	n <sup>b</sup>	% (CI) <sup>ь</sup>	n <sup>ь</sup>	% (CI) <sup>ь</sup>	n <sup>ь</sup>	% (CI)⁵	n <sup>b</sup>	% (CI) <sup>ь</sup>	A vs. B <sup>c</sup>	A vs. B vs. C <sup>d</sup>
Unemployed	262	3 (2, 3)	21	9 (2, 26)	1	1 (0, 3)	239	3 (2, 3)		
Not in work force (retired, student, homemaker)	2,768	29 (28, 31)	62	10 (5, 19)	25	16 (12, 22)	2,680	30 (28, 31)		
Other	23	0 (0, 1)	1	0 (0, 1)	0	0 (0, 0)	22	0 (0, 1)		

275 Abbreviations: ME/CFS= myalgic encephalomyelitis/chronic fatigue syndrome; EHR=electronic health record;

276 CI=95% confidence interval

277 <sup>a</sup>ME/CFS-like illness is defined as self-reported symptoms that meet the Institute of Medicine 2015 ME/CFS

278 criteria: 1) fatigue, post-exertional malaise, and unrefreshing sleep or sleep problems frequently, at a moderate to

severe intensity, and for at least six months; 2) cognitive impairment or orthostatic intolerance frequently, at a

280 moderate to severe intensity, and for at least six months; 3) fatigue must substantially limit one's ability to pursue

work, educational, social, or recreational activities, and rest must not make the fatigue substantially better

b"N" columns are unweighted counts unless otherwise specified in the row label and "% (CI)" columns are
 weighted percentages with 95% confidence intervals unless otherwise specified in the row label

<sup>c</sup>Column contains the p-values comparing the group in column A (ME/CFS-like illness, no ME/CFS diagnosis in EHR)
 to the group in column B (ME/CFS-like illness, ME/CFS diagnosis in EHR) using the chi-squared test with Rao &
 Scott's second-order correction for categorical variables and the Wilcoxon rank-sum test for continuous variables.

P-values are adjusted for multiple comparisons

<sup>288</sup> <sup>d</sup>Column contains the p-values comparing the groups in column A (ME/CFS-like illness, no ME/CFS diagnosis in

EHR), column B (ME/CFS-like illness, ME/CFS diagnosis in EHR), and column C (No ME/CFS-like illness) using the chi squared test with Rao & Scott's second-order correction for categorical variables and the Kruskal-Wallis rank-sum
 test for continuous variables. P-values are adjusted for multiple comparisons

<sup>292</sup> <sup>e</sup>Clinician diagnosis in the EHR based on the following International Classification of Disease [ICD]-9 or ICD-10 codes

293 documented in the EHR: F48.8 ,F51, F51.0, F51.01, F51.02, F51.03, F51.04, F51.05, F51.09, F51.1, F51.11, F51.12,

**294** F51.13, F51.19, F51.8, F51.9, G31.84, G47, G47.0, G47.00, G47.01, G47.09, G47.1, G47.10, G47.11, G47.12, G47.13,

**295** G47.14, G47.19, G47.20, G47.21, G47.22, G47.23, G47.24, G47.27, G47.29, G47.41, G47.411, G47.419, G47.42,

**296** G47.421, G47.429, G47.9, G90.A, I95.1, R40.0, R41.8, R41.840, R41.841, R41.89, R41.9, R53.1, R53.81, R53.83,

**297** 300.5, 300.89, 307.40, 307.41, 307.42, 307.43, 307.44, 307.45, 307.47, 307.48, 307.49, 327.00, 327.01, 327.02,

**298** 327.09, 327.10, 327.11, 327.12, 327.13, 327.14, 327.15, 327.19, 327.30, 327.31, 327.32, 327.33, 327.34, 327.37,

**299** 327.39, 331.83, 347.00, 347.01, 347.10, 347.11, 458.0, 780.09, 780.50, 780.52, 780.54, 780.55, 780.58, 780.79,

300 780.99, 799.3, 799.51, 799.52, 799.59

illness <sup>a</sup> on survey, by presence of ME/CFS diagnosis in the electronic health record (EHR)								
	A. ME/CFS-like illness, no ME/CFS diagnosis in EH		B. ME/ illness, diagnos	CFS-like ME/CFS is in EHR	C. No ME illn	CFS-like ess	p-values	
Characteristic <sup>b</sup>	mean <sup>c</sup>	CIc	mean <sup>c</sup>	CIc	mean <sup>c</sup>	CIc	A vs. B <sup>d</sup>	A vs. B vs. C <sup>e</sup>
SF-36								
Physical functioning (T- score)	38	(34, 42)	31	(29, 32)	50	(49, 50)	0.001	<0.001
Role-physical (T-score)	33	(30, 37)	26	(24, 27)	50	(50, 50)	<0.001	<0.001
Bodily pain (T-score)	35	(33, 38)	35	(33, 36)	51	(51, 51)	0.6	<0.001
Vitality (T-score)	30	(28, 32)	28	(27, 29)	49	(48, 49)	0.033	<0.001
General health (T-score)	34	(31, 37)	28	(27, 30)	47	(47, 47)	<0.001	<0.001
Social functioning (T-score)	29	(26, 32)	25	(24, 26)	47	(46, 47)	0.049	<0.001
Role-emotional (T-score)	30	(27, 33)	29	(27, 32)	46	(46, 47)	0.789	<0.001
Mental health (T-score)	30	(26, 33)	34	(32, 36)	47	(47, 48)	0.033	<0.001
PHQ-8 depression score (0- 24)	16	(14, 17)	15	(14, 16)	6	(5, 6)	0.4	<0.001
GAD-2 anxiety score (0-6)	4	(3, 4)	3	(3, 3)	1	(1, 1)	0.028	<0.001
PROMIS cognitive function (T-score)	36	(34, 38)	32	(31, 33)	52	(51, 52)	0.003	<0.001
OGS Orthostatic intolerance (0-25)	5	(3, 6)	5	(4, 7)	0	(0, 0)	0.4	<0.001

.... . . . . .

301 Abbreviations: ME/CFS= myalgic encephalomyelitis/chronic fatigue syndrome; EHR=electronic health record;

302 CI=95% confidence interval

303 <sup>a</sup>ME/CFS-like illness is defined as self-reported symptoms that meet the Institute of Medicine 2015 ME/CFS

304 criteria: 1) fatigue, post-exertional malaise, and unrefreshing sleep or sleep problems frequently, at a moderate to

305 severe intensity, and for at least six months; 2) cognitive impairment or orthostatic intolerance frequently, at a

306 moderate to severe intensity, and for at least six months; 3) fatigue must substantially limit one's ability to pursue

307 work, educational, social, or recreational activities, and rest must not make the fatigue substantially better

308 <sup>b</sup>36-Item Short Form Health Survey [SF-36], higher score indicates better functioning; Patient Health Questionnaire

309 Depression scale [PHQ-8], higher score indicates higher levels of depression; Generalized Anxiety Disorder scale

310 [GAD-2], higher score indicates higher levels of anxiety; Patient-Reported Outcomes Measurement Information

311 System cognition instrument Adult v2.0 - Cognitive Function 4a [PROMIS cognition], higher score indicates better

312 cognition; Orthostatic Grading Scale [OGS], higher score indicates more orthostatic intolerance

313 <sup>c</sup>"Mean" columns are weighted means, "CI" columns are weighted 95% confidence intervals

314 <sup>d</sup>Column contains the p-values comparing the group in column A (ME/CFS-like illness, no ME/CFS diagnosis in EHR)

315 to the group in column B (ME/CFS-like illness, ME/CFS diagnosis in EHR) using the Wilcoxon rank-sum test. P-values 316 are adjusted for multiple comparisons

317 <sup>e</sup>Column contains the p-values comparing the groups in column A (ME/CFS-like illness, no ME/CFS diagnosis in

318 EHR), column B (ME/CFS-like illness, ME/CFS diagnosis in EHR), and column C (No ME/CFS-like illness) using the

319 Kruskal-Wallis rank-sum test. P-values are adjusted for multiple comparisons

#### Supplemental Table 1. Logic for determining participant grouping into either myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-like illness or No ME/CFS-like illness. ME/CFS-like illness Information from group inclusion medical record that **Responses that** meet inclusion criteria, based on Information from survey that would fulfill inclusion criteria would fulfill inclusion Institute of Medicine criteria criteria (IOM) criteria<sup>a</sup> "1. During the past 4 weeks, have you had Fatigue that All of questions 1 ٠ substantially limits through 6 must be fatigue, tiredness, or exhaustion? activities and is not 0 Yes answered with one of the responses in substantially alleviated No" 0 by rest bold to meet "2. During the past 4 weeks, how often have you inclusion criteria for had fatigue, tiredness, or exhaustion? A little of the time fatigue 0 0 Some of the time A good bit of the time 0 Most of the time 0 All of the time" 0 "3. During the past 4 weeks, how bad was your fatigue, tiredness, or exhaustion? Very mild 0 Mild 0 Moderate 0 0 Severe Very severe" 0 "4. How long have you had fatigue, tiredness, or exhaustion? 0 Less than 6 months 6 months up to 1 year 0 1 year up to 3 years 0 3 years up to 5 years 0 5 years up to 10 years 0 10 or more years" 0 "5. Has your fatigue substantially limited your ability to pursue your work, educational, social, or recreational activities? Yes 0 0 No Not applicable" 0 "6. When you experience fatigue, does rest make your fatigue better? Yes, a lot 0 0 Yes, a little 0 No, not very much No, not at all" 0 Post-exertional "7. During the past 4 weeks, have you been All of questions 7 malaise unusually fatigued or unwell for at least one day through 10 must be after exerting yourself in any way? answered with one Yes of the responses in 0 No" bold to meet 0 inclusion criteria for "8. During the past 4 weeks, how often have you post-exertional had unusual fatigue after exertion? A little of the time malaise 0 Some of the time 0 0 A good bit of the time

Most of the time

"9. During the past 4 weeks, how bad was your

All of the time"

unusual fatigue after exertion? Very mild

Moderate

Severe Very severe"

Mild

0

0

0

0

0 0

	• "10. How long have you had unusual fatigue		
	after exertion?		
	• Less than 6 months		
	• 6 months up to 1 year		
	<ul> <li>1 year up to 3 years</li> </ul>		
	<ul> <li>3 years up to 5 years</li> </ul>		
	<ul> <li>5 years up to 10 years</li> </ul>		
	<ul> <li>10 or more years"</li> </ul>		
Unrefreshing sleep or	• "11. During the past 4 weeks, has unrefreshing		All of questions 11
problems sleeping	sleep been a problem for you?		through 14 OR all of
	o Yes		questions 15
	• No"		through 18 must be
	<ul> <li>"12. During the past 4 weeks, how often have</li> </ul>		answered with one
	you had unrefreshing sleep?		of the responses in
	<ul> <li>A little of the time</li> </ul>		bold to meet
	• Some of the time		inclusion criteria for
	• A good bit of the time		unrefreshing sleep
	• Most of the time		or problems sleeping
	• All of the time		
	<ul> <li>13. During the past 4 weeks, now much of a problem was uprofreshing sleep?</li> </ul>		
	problem was unreneshing sleep?		
	o Mild		
	• Verv severe"		
	• "14. How long had you had unrefreshing sleep?		
	• Less than 6 months		
	• 6 months up to 1 year		
	<ul> <li>1 year up to 3 years</li> </ul>		
	<ul> <li>3 years up to 5 years</li> </ul>		
	<ul> <li>5 years up to 10 years</li> </ul>		
	<ul> <li>10 or more years"</li> </ul>		
	OR	-	
	• "15 During the past 4 weeks have you had		
	<ul> <li>IS. During the past 4 weeks, have you had</li> <li>nroblems getting to sleep, sleeping through the</li> </ul>		
	night or waking up on time?		
	o Yes		
	• No"		
	• "16. During the past 4 weeks, how often have		
	you had sleeping problems?		
	<ul> <li>A little of the time</li> </ul>		
	<ul> <li>Some of the time</li> </ul>		
	<ul> <li>A good bit of the time</li> </ul>		
	<ul> <li>Most of the time</li> </ul>		
	<ul> <li>All of the time"</li> </ul>		
	• "17. During the past 4 weeks, how bad were		
	these sleeping problems?		
	• Very mild		
	o Mild		
	• "18 How long have you had slooping problems?		
	Less than 6 months		
	<ul> <li>6 months up to 1 year</li> </ul>		
	o 1 year up to 3 years		
	• 3 years up to 5 years		
	<ul> <li>5 years up to 10 years</li> </ul>		
	<ul> <li>10 or more years"</li> </ul>		
Cognitive impairment	• "19. During the past 4 weeks, have you had		All of questions 19
	forgetfulness or memory problems that caused	-	through 22 OR all of
	you to substantially cut back on your activities?		questions 23

	<ul> <li>Yes         <ul> <li>No"</li> </ul> </li> <li>"20. During the past 4 weeks, how often have you had forgetfulness or memory problems?         <ul> <li>A little of the time</li> <li>Some of the time</li> <li>A good bit of the time</li> <li>Most of the time</li> <li>Most of the time</li> <li>Most of the time</li> <li>Most of the time</li> <li>Very mild</li> <li>Moderate</li> <li>Severe</li> <li>Very severe"</li> </ul> </li> <li>"21. During the past 4 weeks, how bad were your forgetfulness or memory problems?         <ul> <li>Very mild</li> <li>Moderate</li> <li>Severe</li> <li>Very severe"</li> </ul> </li> <li>"22. How long have you had forgetfulness or memory problems?         <ul> <li>Less than 6 months</li> <li>6 months up to 1 year</li> <li>1 year up to 3 years</li> <li>3 years up to 10 years</li> <li>Severe just on 10 years</li> <li>10 or more years"</li> <li>OR</li> </ul> </li> <li>"23. During the past 4 weeks, have you had difficulty with thinking or concentrating that caused you to substantially cut back on your activities?             <ul> <li>Yes</li> <li>No"</li> </ul> </li> <li>"24. During the past 4 weeks, how often have you had difficulty with thinking or concentrating?             <ul> <li>A little of the time</li> <li>Some of the time</li> <li>Some of the time</li> <li>A good bit of the time</li> <li>All of the time"</li> <li>All of the time"</li> <li>Very mild</li> <li>Most of the time</li> <li>All of the time"</li> <li>Very mild</li> <li>Moderate</li> <li>Severe</li></ul></li></ul>	through 26 must be answered with one of the responses in bold to meet inclusion criteria for cognitive impairment
	<ul> <li>Very severe"</li> </ul>	
	<ul> <li>"26. How long have you had difficulty with thinking or concentration?"</li> </ul>	
	Concentrating?     O Less than 6 months	
	<ul> <li>6 months up to 1 year</li> </ul>	
	• 1 year up to 3 years	
	• 3 years up to 5 years	
	<ul> <li>S years up to 10 years</li> <li>10 or more years"</li> </ul>	
Orthostatic	• "27. During the past 4 weeks, have you had	All of questions 27
intolerance	dizziness or fainting problems?	through 30 must be
	○ Yes ○ No"	answered with one of the responses in
	"28. During the past 4 weeks, how often have	- bold to meet
	you had dizziness or fainting problems?	inclusion criteria for
	• A little of the time	orthostatic
	Some of the time     A good bit of the time	

	• Most of the time	
	<ul> <li>All of the time"</li> </ul>	
• "29.	During the past 4 weeks, how had was your	
dizzi	ness or fainting problems?	
	<ul> <li>Verv mild</li> </ul>	
	• Mild	
	• Moderate	
	• Severe	
	<ul> <li>Verv severe"</li> </ul>	
• "30	How long have you had dizziness or fainting	
nroh	lems?	
p.00	<ul> <li>Less than 6 months</li> </ul>	
	<ul> <li>6 months up to 1 year</li> </ul>	
	<ul> <li>1 year up to 3 years</li> </ul>	
	<ul> <li>3 years up to 5 years</li> </ul>	
	<ul> <li>5 years up to 5 years</li> <li>5 years up to 10 years</li> </ul>	
	<ul> <li>J years up to 10 years</li> <li>10 or more years"</li> </ul>	
If participants met all three of the fatigue.	post-exertional malaise, and unrefreshing sl	eep or problems sleeping criteria, plus either the
cognitive impairment or the orthostatic in	tolerance criteria they were sorted into the	ME/CES-like illness category Otherwise they were
cognitive impairment of the ofthostatie in	torerance enteria, they were solited into the	They are miness category. Otherwise, they were

sorted into the No ME/CFS-like illness category. This logic was applied to both year one and year two participants based on the data in that year's survey only; for participants who answered the survey both years, their year two category does not take into account their year one category.

<sup>a</sup>Institute of Medicine (U.S.), editor. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. Washington, D.C: The National Academies Press; 2015. 1 p.